​Bio-Pharmaceutical Innovation

 

 

 

We at Princeton Biotechnology are using

innovative new drug development tools to expeditiously ​produce powerful new medicines ​

​​

​The future of medicine is moving inexorably towards

drugs that produce fast results, are safe and easy to use,

and have no unwanted side effects. 

​

The new marketplace imperative is:  Primum non nocere,

the​ Latin phrase that states: First Do No Harm.  This important concept was generally supposed to be part and parcel of health and healing in the world today, but now with iatrogenic patient mortality at the rate of 4,000+ per week (these were trusting patients who were earnestly following their doctors' prescription drug directions), more and more patients and their doctors find this unacceptable.   Somewhere along the way First Do No Harm seems to have gotten lost; as anyone today listening to the repetitious "Ask your Doctor" television commercials can attest, the litany of unwanted side effects that they promote has now reached such egregious proportions that they are eroding the public's trust. 

​

To counteract this trend, we at Princeton Biotechnology were prompted to develop a prescription drug (AHEALON®) that was so powerful, yet also so completely safe, that the public would start to re-establish its trust in the practice of traditional medicine.

​

The bellwether of public opinion has already sounded, and the time has come to retire the old, overused buggy whip and its undesirable side effects, and replace it with much more humanity and compassion. 

​

We are now all a part of this exciting transition to a new golden age of safe health and healing, where First Do No Harm is again reinstated back into the practice of medicine.      

​​To comply with these new marketplace demands, we at Princeton Biotechnology are working very hard to be among the new companies who will emerge as world leaders in this new era of medicine.  We expect to supply innovative drugs, such as AHEALON®, that will meet the new compassionate and compelling marketplace acceptance criteria of effective and safe medicine for everyone.

​​

It is expected that a new wave of innovative medicine providers will quickly move to answer these new marketplace demands.  Within these new guidelines, we at Princeton Biotechnology plan to produce a dynamic family of breakthrough world class medicines that will be our contribution to the new demands for effective, safe health and healing, that will soon become the new world standard.  To help us in this endeavor we are fortunate to have developed a heuristic new drug development platform. ​

 

 

​This unique developmental platform helped us at Princeton Biotechnology to recently develop the exciting, new world class drug AHEALON®. 

​

​

AHEALON

​

​​Generally topically applied AHEALON® is an impressive, multifaceted 6-in-1 General Purpose Prescription Medicine for:

​

        1.  Pain mitigation/cessation​

        2.  Inflammation reduction

        3.  Infection reduction

        4.  A healing stimulus

        5.  Scar tissue minimization

        6   Wound bed moisturization

​

AHEALON® is also:

​cccccc

        Easy to use

        Easy to prescribe

        Fast acting

        Safe, with no unwanted side effects

​   

        USA FDA NDC 52793-700-02       

​

To get all of the above abilities and attributes to effectively work together, and to reside within just one prescription formulation, took many ​years of diligent bio-pharmacological engineering.  We at Princeton Biotechnology finally succeeded when everything came together ​with the help of our innovative new drug development platform. 

​

With our unique new drug development tools, together with the knowledge acquired from all of the drugs being developed in our new drug pipeline, we at Princeton Biotechnology believe that we can additionally and expeditiously produce (within 6 - 12 months) a substantial number of very effective prescription drugs, each designed for a specifically targeted therapeutic community. 

​

Each of these new medicines will be able to uniquely and effectively address major etiological components of specifically targeted disease/malady mechanisms, while importantly also meeting the new market imperative of being effective, fast acting and safe.

​

​

 

  

Princeton Biotechnology

Pharmacological Areas

of Interest

​

​Princeton Biotechnology; some developmental areas of interest: 

               

      ​Burn wounds

      Trigeminal Neuralgia

      Neuropathic Pain

      Rheumatoid Arthritis​​​

      Skin maladies

      Pressure sores/ulcers, Bed sores

      Non-healing wounds

      Radiation Dermatitis

      GI / mouth, acid reflux, ulcers, ulcerative colitis, Crohn's

      Respiratory / COPD, RSV, sinus, asthma

      Oncology

      Adjuvants

 

 

 

 

​

AHEALON®    USA FDA NDC 52793-700-02

​xxxx           

                        Prescription Insert:            Brochure::